Table 4

Serum IGFs,a IGFBPs, and CA125 levels in the women with recurrent disease compared to the women remaining in remission

Relapse Mean ± SERemission Mean ± SEPb
Total number4513
Median age62 years60 years
Range(32–79 years)(47–70 years)
Median time between diagnosis and relapse, monthsRange10 (3–26)
StagecI/II110
III/IV453
Degree of differentiationdWell14
Mod well158
Poorly291
SurgeryeOptimal1313
Suboptimal32
IGFBP-2 level at diagnosis (ng/ml)900 ± 89565 ± 82P = 0.037
IGFBP-2 level at relapse1194 ± 139P = 0.01
IGFBP-2 level at follow-up324 ± 60P = 0.027
IGFBP-3 level at diagnosis (μg/ml)3.25 ± 0.322.6 ± 0.15NS
IGFBP-3 level at relapse2.96 ± 0.3NS
IGFBP-3 level at follow-up4.3 ± 0.19P < 0.0001
IGF-I level at diagnosis (nmol/L)8.8 ± 0.677.5 ± 1
IGF-I level at relapse11.4 ± 1.2NS
IGF-I level at follow-up15.4 ± 1.3P < 0.0001
IGFBP-5 level at diagnosis (ng/ml)79.4 ± 3.978.8 ± 4.6NS
IGFBP-5 level at relapse121.8 ± 8.5P < 0.0001
IGFBP-5 level at follow-up139.6 ± 9P < 0.0001
CA 125 level at diagnosis (U/ml)2025 ± 809461 ± 170NS
CA 125 level at relapse959 ± 302NS
CA 125 level at follow-up7.6 ± 1.2P = 0.06
  • a IGF, insulin-like growth factor; IGFBP, insulin-like growth factor binding protein; NS, non-significant (P > 0.05).

  • b P, probability of a difference between the growth factor level at diagnosis and follow-up or relapse, via ANOVA and Kruskal-Wallis test as appropriate.

  • c Surgical stage (International Federation of Gynaecology and Obstetrics 1987).

  • d Cellular differentiation (WHO Classification 1989).

  • e Degree of debulking surgery (Substages in Advanced Ovarian Cancer 1992).